価格表

在庫・価格 : 2024年04月29日 10時33分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Glucagon ELISA Kit, Mercodia (96well)
10-1271-01 MRDメルコディア
Mercodia AB
1 kit 本製品は製品内容等が変更されました 変更先製品 追加

在庫・価格 : 2024年04月29日 10時33分 現在

Glucagon ELISA Kit, Mercodia (96well)

  • 商品コード:10-1271-01
  • メーカー:MRD
  • 包装:1kit
  • 本製品は製品内容等が変更されました 変更先製品
使用文献
No. 文献情報 備考 参照
1 Chow SZ et al. Gp130 receptor signaling mediates α cell dysfunction in a rodent model of type 2 diabetes. Diabetes. 2014 May.
Chow SZ et al
2014/01/01
PubMed
2 Alsalim W et al. Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes. Diabetes Obes Metab 2016 Jan;18(1):24-33
Alsalim W et al
2016/01/01
PubMed
3 Bennet H et al. Altered serotonin (5-HT) 1D and 2A receptor expression may contribute to defective insulin and glucagon secretion in human type 2 diabetes. Peptides 2015 Sep;71:113-20
Bennet H et al
2015/01/01
PubMed
4 Hall MJ et al. Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats. Domest. Anim. Endocrinol. 2015 Apr;51:114-21
Hall MJ et al
2015/01/01
PubMed
5 Heddad Masson M et al. Foxa1 and Foxa2 regulate α-cell differentiation, glucagon biosynthesis, and secretion. Endocrinology 2014 Oct;155(10):3781-92
Heddad Masson M et al
2014/01/01
PubMed
6 Hu J et al. Effect of combined therapy of human Wharton"s jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats. Endocrine 2014 Mar;45(2):279-87
Hu J et al
2014/01/01
PubMed
7 Ilkowitz JT et al. Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial. J Diabetes Sci Technol 2016 Sep;10(5):1108-14
Ilkowitz JT et al
2016/01/01
PubMed
8 Komiya C et al. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS ONE 2016;11(3):e0151511
Komiya C et al
2016/01/01
PubMed
9 Lund A et al. Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes 2016 Mar;65(3):585-97
Lund A et al
2016/01/01
PubMed
10 Malmgren S et al. DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice. Diabetologia 2015 May;58(5):1091-9
Malmgren S et al
2015/01/01
PubMed
11 Manell H et al. Altered Plasma Levels of Glucagon, GLP-1 and Glicentin During OGTT in Adolescents With Obesity and Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2016 Mar;101(3):1181-9
Manell H et al
2016/01/01
PubMed
12 Matsuo T et al. Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme-linked immunosorbent assay. J Diabetes Investig 2016 May;7(3):324-31
Matsuo T et al
2016/01/01
PubMed
13 Pedersen MG et al. Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. Sci Rep 2016;6:31214
Pedersen MG et al
2016/01/01
PubMed
14 S旦der J et al. Metabolic and Hormonal Response to a Feed-challenge Test in Lean and Overweight Dogs. J. Vet. Intern. Med. ;30(2):574-82
S旦der J et al
PubMed
15 Stamenkovic JA et al. Inhibition of the malate-aspartate shuttle in mouse pancreatic islets abolishes glucagon secretion without affecting insulin secretion. Biochem. J. 2015 May;468(1):49-63
Stamenkovic JA et al
2015/01/01
PubMed
16 Sterl K et al. Metabolic responses to xenin-25 are altered in humans with Roux-en-Y gastric bypass surgery. Peptides 2016 Aug;82:76-84
Sterl K et al
2016/01/01
PubMed
17 Tric嘆 D et al. Sustained effects of a protein and lipid preload on glucose tolerance in type 2 diabetes patients. Diabetes Metab. 2016 Sep;42(4):242-8
Tric嘆 D et al
2016/01/01
PubMed
18 Wewer Albrechtsen NJ et al. Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion. J Diabetes Res 2016;2016:8352957
Wewer Albrechtsen NJ et al
2016/01/01
PubMed
  • No.: 1
  • 文献情報:
    Chow SZ et al. Gp130 receptor signaling mediates α cell dysfunction in a rodent model of type 2 diabetes. Diabetes. 2014 May.
    Chow SZ et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Alsalim W et al. Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes. Diabetes Obes Metab 2016 Jan;18(1):24-33
    Alsalim W et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Bennet H et al. Altered serotonin (5-HT) 1D and 2A receptor expression may contribute to defective insulin and glucagon secretion in human type 2 diabetes. Peptides 2015 Sep;71:113-20
    Bennet H et al
    2015/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Hall MJ et al. Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats. Domest. Anim. Endocrinol. 2015 Apr;51:114-21
    Hall MJ et al
    2015/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Heddad Masson M et al. Foxa1 and Foxa2 regulate α-cell differentiation, glucagon biosynthesis, and secretion. Endocrinology 2014 Oct;155(10):3781-92
    Heddad Masson M et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Hu J et al. Effect of combined therapy of human Wharton"s jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats. Endocrine 2014 Mar;45(2):279-87
    Hu J et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Ilkowitz JT et al. Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial. J Diabetes Sci Technol 2016 Sep;10(5):1108-14
    Ilkowitz JT et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Komiya C et al. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS ONE 2016;11(3):e0151511
    Komiya C et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Lund A et al. Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes 2016 Mar;65(3):585-97
    Lund A et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Malmgren S et al. DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice. Diabetologia 2015 May;58(5):1091-9
    Malmgren S et al
    2015/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Manell H et al. Altered Plasma Levels of Glucagon, GLP-1 and Glicentin During OGTT in Adolescents With Obesity and Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2016 Mar;101(3):1181-9
    Manell H et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Matsuo T et al. Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme-linked immunosorbent assay. J Diabetes Investig 2016 May;7(3):324-31
    Matsuo T et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Pedersen MG et al. Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. Sci Rep 2016;6:31214
    Pedersen MG et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    S旦der J et al. Metabolic and Hormonal Response to a Feed-challenge Test in Lean and Overweight Dogs. J. Vet. Intern. Med. ;30(2):574-82
    S旦der J et al
  • 備考:
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Stamenkovic JA et al. Inhibition of the malate-aspartate shuttle in mouse pancreatic islets abolishes glucagon secretion without affecting insulin secretion. Biochem. J. 2015 May;468(1):49-63
    Stamenkovic JA et al
    2015/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Sterl K et al. Metabolic responses to xenin-25 are altered in humans with Roux-en-Y gastric bypass surgery. Peptides 2016 Aug;82:76-84
    Sterl K et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 17
  • 文献情報:
    Tric嘆 D et al. Sustained effects of a protein and lipid preload on glucose tolerance in type 2 diabetes patients. Diabetes Metab. 2016 Sep;42(4):242-8
    Tric嘆 D et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 18
  • 文献情報:
    Wewer Albrechtsen NJ et al. Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion. J Diabetes Res 2016;2016:8352957
    Wewer Albrechtsen NJ et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed